Identifying Outcomes in Clinical Trials of Fistulizing Crohn’s Disease for the Development of a Core Outcome Set.

Identifying Outcomes in Clinical Trials of Fistulizing Crohn’s Disease for the Development of a Core Outcome Set. Clin Gastroenterol Hepatol. 2018 Oct 04;: Authors: Ma C, Parker CE, Nguyen TM, Khanna R, Feagan BG, Jairath V PMID: 30292887 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30292887?dopt=Abstract

Read More

No Change in Determining Crohn’s Disease Recurrence or Need for Endoscopic or Surgical Intervention With Modification of Rutgeerts’ Scoring System.

No Change in Determining Crohn’s Disease Recurrence or Need for Endoscopic or Surgical Intervention With Modification of Rutgeerts’ Scoring System. Clin Gastroenterol Hepatol. 2018 Oct 03;: Authors: Rivière P, Vermeire S, Irles-Depe M, Van Assche G, Rutgeerts P, de Buck van Overstraeten A, Denost Q, Wolthuis A, D’Hoore A, Laharie D, Ferrante M PMID: 30291910 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30291910?dopt=Abstract

Read More

Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases.

Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018 Sep 26;: Authors: Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, Winters A, Chablaney S, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Hartke JG, Chilukuri P, Bohm M, Sagi SV, Fischer M, Lukin D, Hudesman D, Chang S, Gao Y, Sultan K, Swaminath A, Gupta N, Kane S, Loftus EV, Shen B, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS Abstract BACKGROUND & AIMS: There…

Read More

Combination Therapy with Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy-a Post-hoc analysis.

Combination Therapy with Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy-a Post-hoc analysis. Clin Gastroenterol Hepatol. 2018 Sep 26;: Authors: Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D’Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB Abstract BACKGROUND & AIMS: Among immunosuppressive- and biologic-naïve patients with moderate to severely active Crohn’s disease (CD), a higher proportion of those treated with the combination of infliximab and azathioprine achieved corticosteroid-free remission at week 26 (CSFR26) than those given infliximab monotherapy; patients given the combination therapy also had…

Read More

Family History is Associated With Increased Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases.

Family History is Associated With Increased Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018 Sep 26;: Authors: Samadder NJ, Valentine JF, Guthery S, Singh H, Bernstein CN, Leighton JA, Wan Y, Wong J, Boucher K, Pappas L, Rowe K, Burt RW, Curtin K, Smith KR Abstract BACKGROUND & OBJECTIVES: Individuals with inflammatory bowel diseases (IBD) carry an increased risk of developing colorectal cancer (CRC). Though family history of CRC is a well-established risk factor in healthy individuals, its role in IBD patients is less…

Read More

Outcomes of Endoscopic Balloon Dilation vs Surgical Resection for Primary Ileocolic Strictures in Patients With Crohn’s Disease.

Outcomes of Endoscopic Balloon Dilation vs Surgical Resection for Primary Ileocolic Strictures in Patients With Crohn’s Disease. Clin Gastroenterol Hepatol. 2018 Oct;16(10):1682-1683 Authors: Li JD, Xu XF, Xing H PMID: 30243356 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30243356?dopt=Abstract

Read More
<< Go Back